Literature DB >> 6278070

Further evidence for common antigens in herpes simplex and varicella-zoster viruses.

N J Schmidt.   

Abstract

To elucidate the mechanism of heterologous antibody responses to herpes simplex virus (HSV) and varicella-zoster virus (VZV) which occur in some patients with HSV or VZV infections, stronger evidence was sought for the existence of cross-reacting antibodies to these viruses, using antibody absorption procedures. Absorption of sera from initial HSV infections with HSV antigen was found to abolish heterologous antibody titer rises to VZV, as demonstrated in complement fixation, neutralization, and anti-complement immunofluorescence test systems. In most instances, convalescent-phase titers to heterologous VZV were reduced by HSV absorption to levels comparable to those in the acute-phase serum, indicating that cross-reacting antibodies were, in fact, responsible for the heterologous antibody titer rises. Absorption of convalescent-phase sera from HSV or VZV patients with homologous antigen also abolished or greatly diminished immunoprecipitating activity with the heterologous antigen, furnishing additional evidence of the existence of cross-reacting antibodies. Absorption of sera with insolubilized IgG to re-remove rheumatoid factor, which was present in a number of the sera studied, had no effect on either homologous or heterologous antibody titer increases. The demonstration of cross-reacting antibodies to HSV and VZV supports the concept that these two human herpesviruses share common antigen(s).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278070     DOI: 10.1002/jmv.1890090105

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

2.  Establishment by enzyme-linked immunosorbent assay of seronegative range for herpes simplex virus and cytomegalovirus antibodies and evaluation of heterologous responses to live varicella vaccine.

Authors:  A K Gong; S V Lipton; P A Brunell
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Anomalous antibody responses in viral infection: specific stimulation or polyclonal activation?

Authors:  N E Cremer; V L Devlin; J L Riggs; S J Hagens
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

4.  Anti-herpes simplex type 1 activity in IgG subclasses produced systemically and intrathecally in patients with herpes encephalitis.

Authors:  P J Johansson; J Blomberg
Journal:  J Neurol       Date:  1986-10       Impact factor: 4.849

5.  Long-term persistence of intrathecal virus-specific antibody responses after herpes simplex virus encephalitis.

Authors:  B Vandvik; B Sköldenberg; M Forsgren; G Stiernstedt; S Jeansson; E Norrby
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

6.  Enzyme-linked immunosorbent assay for detection of antibody to human herpesvirus 6.

Authors:  K Chokephaibulkit; P A Brunell; V Vimal; C Long; K Schnabel; C B Hall
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

7.  Immunological diagnosis in viral infections of the central nervous system: course of antibody titres against homo- and heterologous viruses.

Authors:  R H Dennin; E Herb
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

8.  Peripheral facial palsy and infections- findings and problems.

Authors:  T Mertens; J P Thomas; C Zippel; H J Eggers
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

9.  Comparative immunohistochemical study of herpes simplex and varicella-zoster infections.

Authors:  A F Nikkels; S Debrus; C Sadzot-Delvaux; J Piette; P Delvenne; B Rentier; G E Piérard
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Herpes simplex virus encephalitis: intrathecal synthesis of oligoclonal virus-specific IgG, IgA and IgM antibodies.

Authors:  B Vandvik; F Vartdal; E Norrby
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.